Drug
Bnt3219
Bnt3219: highest development phase Phase 1, developed by BioNTech. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- BioNTech
Trials
| Drug | Phase | Indication |
|---|---|---|
| BNT3219 NCT07893054 | Phase 1 | Advanced Solid Tumors |
Latest
No recent events.
Follow Bnt3219 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.